See How Investors Reacted to Cubist Pharmaceuticals Earnings and 3 More Healthcare Stocks

Quest Diagnostics Inc. (NYSE:DGX) delivered a profit and missed Wall Street’s expectations, AND came up short on beating the revenue expectation. Net income decreased -70.54% to $55.8 million (34 cents per diluted share) in the quarter versus a net gain of $189.44 million in the year-earlier quarter. Revenue decreased 5.82% to $1.77 billion from the year-earlier quarter.

Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now!

Quest Diagnostics Inc. reported adjusted net income of $1.01 cents per share. By that measure, the company missed the mean analyst estimate of $1.02. It missed the average revenue estimate of $1.8 billion.

DGX

Abbott Laboratories (NYSE:ABT) generated a profit and topped Wall Street’s expectations, AND beat the revenue expectation. Net income decreased -35.13% to $1.05 billion (66 cents per diluted share) in the quarter versus a net gain of $1.62 billion in the year-earlier quarter. Revenue rose 4.07% to $10.8 billion from the year-earlier quarter.

Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now!

Abbott Laboratories reported adjusted net income of $1.51 per share. By that measure, the company beat the mean analyst estimate of $1.5. It beat the average revenue estimate of $10.58 billion.

ABT

Stryker Corp. (NYSE:SYK) delivered a profit and beat Wall Street’s expectations, AND beat the revenue expectation. Net income decreased -32.67% to $270 million (71 cents per diluted share) in the quarter versus a net gain of $401 million in the year-earlier quarter. Revenue rose 5.64% to $2.34 billion from the year-earlier quarter.

Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now!

Stryker Corp. reported adjusted net income of $1.14 per share. By that measure, the company beat the mean analyst estimate of $1.13. It beat the average revenue estimate of $2.27 billion.

SYK

Cubist Pharmaceuticals Inc. (NASDAQ:CBST) delivered a profit and beat Wall Street’s expectations, BUT came up short on beating the revenue expectation. Net income increased 454.25% to $37.8 million (51 cents per diluted share) in the quarter versus a net gain of $6.82 million in the year-earlier quarter. Revenue rose 15.49% to $245.9 million from the year-earlier quarter.

Cubist Pharmaceuticals Inc. reported adjusted net income of 51 cents per share. By that measure, the company beat the mean analyst estimate of $0.48. It missed the average revenue estimate of $246.46 million.

CBST

Don’t Miss: IPOs, Lawsuits, and Cancer Treatments: Healthcare Recap.